Europe — EMA

Onnimia (Fulvestrant)

Fulvestrant, the active ingredient in Onnimia, is a selective estrogen receptor degrader presented as a 250 mg/mL solution for intramuscular injection use.

Fulvestrant

Request sourcing

Pack/s

What is Fulvestrant?

Fulvestrant, the active ingredient in Onnimia, is a selective estrogen receptor degrader presented as a 250 mg/mL solution for intramuscular injection use. It treats hormone receptor‑positive metastatic breast cancer in post‑menopausal women. GNH USA supplies Onnimia as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Onnimia as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

What is Fulvestrant used for?

Onnimia is a selective estrogen receptor degrader that targets hormone‑driven breast cancer pathways.

- Metastatic breast cancer: Improves progression‑free survival in post‑menopausal women with estrogen‑receptor‑positive disease. - Hormone‑responsive tumors: Reduces tumor growth by degrading estrogen receptors. - Advanced disease after endocrine therapy: Provides an alternative mechanism when prior endocrine agents have failed.

What are the side effects of Fulvestrant?

Common Side Effects: - Injection site pain - Hot‑tause t t t t t - t t ....

Serious or Rare ":[ {"q": "What "}, {"q": ""}]

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →